A waiver of documentation of informed consent is a narrower IRB action than it sounds: the participant’s signature on a consent form is waived, but informed consent itself — the disclosure of the study’s purpose, risks, benefits, and the participant’s voluntary agreement to take part — still has to happen. This is easy to confuse with a full waiver of informed consent, where the IRB allows the consent process itself to be skipped entirely. The two sit under different sections of the Common Rule, are approved against different criteria, and get documented differently in the protocol record. Confusing them on an IRB submission is one of the more common paperwork errors research teams make.
The regulatory basis: 45 CFR 46.117(c)
Under the Common Rule, documentation of consent is regulated separately from the consent process itself. General consent requirements sit at 45 CFR 46.116; the requirement that consent normally be documented with a signed form sits at 45 CFR 46.117. Section 46.117(c) lets an IRB waive that signed-form requirement — and only that requirement — when it finds either of two conditions:
- The signed form would be the only link between the participant and the study, and the principal risk is a breach of confidentiality. In this case, each participant must be asked whether they want documentation linking them to the research, and their wishes govern.
- The research is minimal risk and involves no procedures for which written consent is normally required outside a research context. Anonymous or low-risk surveys, brief observational studies, and similar minimal-risk designs commonly qualify.
Either finding is sufficient on its own; the IRB does not need to establish both. What it must do is document, in the protocol record, which of the two grounds it relied on and why.
What still has to happen even with the waiver
A documentation waiver removes the signature requirement, not the substance of consent. The investigator must still:
- Disclose the required elements of consent under 45 CFR 46.116(b) — purpose, procedures, risks, benefits, alternatives, confidentiality protections, and the other standard elements, whether reviewed under Subpart A alone or, for FDA-regulated products, alongside 21 CFR 50.25.
- Confirm the participant understands what they’re agreeing to and is participating voluntarily.
- Give the participant a written information sheet or fact sheet describing the study, unless the IRB specifically finds that unnecessary (for example, a purely oral consent script for an anonymous phone survey).
In practice, IRBs typically approve a consent information sheet or oral script in place of a signature block, and the investigator retains that document as evidence the consent process took place — it just isn’t signed by the participant.
Documentation waiver vs. full waiver of consent: not the same thing
These two mechanisms are frequently conflated in casual conversation and occasionally in draft protocols, but they rest on different regulatory tests and different IRB findings.
| Waiver of documentation (46.117(c)) | Waiver of the consent process (46.116(f)) | |
|---|---|---|
| What’s waived | Only the signed consent form | The consent process itself — no consent is obtained at all |
| Does a consent conversation/disclosure still occur? | Yes, required | No |
| Regulatory test | Two alternative grounds: confidentiality-breach-is-the-principal-risk, OR minimal risk with no procedures normally requiring written consent outside research | Five-part test: minimal risk; not practicable without the waiver; not practicable without identifiable data/biospecimens if used; no adverse effect on rights/welfare; debriefing where appropriate |
| Typical use case | Anonymous or low-risk surveys; studies where a signed name is itself the confidentiality risk (e.g., a survey about illegal drug use or immigration status) | Retrospective chart review, registry research, and other secondary-data studies where re-contacting every prior subject isn’t practicable |
For the full mechanism and its five-part test, see Waiver of Informed Consent: When an IRB Can Approve Research Without It and the underlying dictionary entry, Waiver of Informed Consent (45 CFR 46.116(f)). This page covers only the narrower documentation waiver under 46.117(c).
How this differs from short-form consent
A documentation waiver is also sometimes confused with short-form written consent under 45 CFR 46.117(b)(2) (paralleled at 21 CFR 50.27(b)(2) for FDA-regulated research). Short-form consent is used when a participant can’t read the standard IRB-approved long-form document — commonly a non-English speaker where no translated long form exists. The required elements are read aloud with a witness present, the IRB approves a written summary of what was said, and the participant (or their legally authorized representative) still signs the short form itself, with the witness signing both the short form and a copy of the summary. In other words, short-form consent still involves a signature; a 46.117(c) documentation waiver does not require one at all. They’re both mechanisms under the same section of the regulation but solve different problems.
FDA-regulated research: the parallel provision
For research subject to FDA jurisdiction (drugs, biologics, devices reviewed under an IND or IDE), the equivalent mechanism is 21 CFR 56.109(c)(1), which lets an IRB waive the requirement for the investigator to obtain a signed consent form under materially the same criteria as 46.117(c). Until a 2024 FDA rule change, this documentation waiver and the narrow emergency-research exception at 21 CFR 50.24 were the only waiver mechanisms available in FDA-regulated research — there was no FDA equivalent to the Common Rule’s full consent-process waiver. That changed when FDA added 21 CFR 50.22, implementing Section 3024 of the 21st Century Cures Act, giving FDA-regulated minimal-risk studies a waiver-of-consent pathway roughly parallel to 45 CFR 46.116(f) for the first time. That’s a separate, more consequential change covered in the full waiver guide linked above; the documentation-only waiver under 56.109(c)(1) is unaffected by it and continues to work the same way it always has.
Common scenarios where a documentation waiver applies
- Sensitive-topic surveys. A study asking about illicit drug use, sexual behavior, immigration status, or similarly stigmatized or legally risky topics, where a signed name on file would itself be the main risk to the participant if the records were ever breached or subpoenaed.
- Low-risk anonymous or online surveys. Brief, minimal-risk questionnaires where written consent outside a research context wouldn’t normally be expected for an equivalent activity.
- Brief phone or field interviews. Minimal-risk interview studies conducted quickly in the field, where obtaining a physical signature isn’t practicable and the study doesn’t otherwise involve procedures that would normally require one.
A documentation waiver is not a shortcut for higher-risk research, and it doesn’t apply just because collecting signatures is inconvenient for the study team — the IRB has to make and record one of the two 46.117(c) findings specifically.
What to include in an IRB submission requesting this waiver
- A clear statement of which of the two 46.117(c) grounds applies (confidentiality-breach-as-principal-risk, or minimal-risk-with-no-normally-required-written-consent), not just a general request to skip signatures.
- If relying on the confidentiality-breach ground, a description of how participants will be asked whether they want a signed record linking them to the study.
- The consent information sheet, fact sheet, or oral script that will still be used to convey the required 46.116(b) elements.
- For FDA-regulated studies, a citation to 21 CFR 56.109(c)(1) rather than (or in addition to) 46.117(c), since the sponsor and monitors will expect the FDA-track citation.
Frequently asked questions
Does a documentation waiver mean participants don’t have to consent at all?
No. Informed consent still has to be obtained and documented in the study record in some form — typically an information sheet or a scripted oral disclosure. Only the participant’s signature is waived. If no consent process is occurring at all, that’s a waiver of the consent process itself under 46.116(f), a different and more demanding mechanism covered separately.
Can an IRB grant a documentation waiver for a greater-than-minimal-risk study?
Only under the confidentiality-breach ground, and only where the signed form itself is genuinely the principal risk to participants (for example, a study on a criminalized or stigmatized behavior). The second ground — minimal risk with no procedures normally requiring written consent — is unavailable for anything above minimal risk.
Is a documentation waiver the same as verbal consent?
They commonly go together in practice — a study granted a documentation waiver often uses an oral consent script — but the waiver is the regulatory action (excusing the signature requirement); verbal or oral consent describes how the disclosure is actually delivered to the participant. An IRB could, in principle, waive documentation while still requiring the process to be delivered in writing.
Does this apply automatically to online or anonymous surveys?
No. An IRB still has to review the specific study and make one of the two required findings under 46.117(c) (or 21 CFR 56.109(c)(1) for FDA-regulated research). Anonymous, minimal-risk surveys are a common candidate for this waiver, but approval isn’t automatic just because a survey is anonymous.
See also: Informed Consent, The Components of Informed Consent, Informed Consent Checklist for Researchers, and HIPAA Waiver or Alteration of Authorization for Research Use of PHI for the parallel HIPAA-side waiver mechanism.
